Rheumatology 2003; 42: 235-239
© 2003 British Society for Rheumatology
Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients
Clinical Immunology Unit, Queens Medical Centre, Nottingham NG7 2UH, UK
Objective. To assess the effects prospectively of tumour necrosis factor (TNF) receptor superfamily (TNFRSF) fusion proteins TNFRSF1B (etanercept) and TNFRSF1A (p55TNFr-Ig) in patients with TNF receptor associated periodic syndrome (TRAPS).
Methods. Seven patients with a clinical and genetic diagnosis of TRAPS received subcutaneous etanercept for 24 weeks. One of these patients had previously received an intravenous infusion of p55TNFr-Ig. Therapeutic response was assessed by comparing corticosteroid requirement, acute-phase response and an established scoring system over 20 weeks, both on and off etanercept.
Results. Etanercept was well tolerated. The five corticosteroid-responsive patients required significantly less corticosteroids and demonstrated reductions in acute-phase reactants on etanercept. The two patients not requiring corticosteroids had small reductions in disease activity scores. The effect of p55TNFr-Ig in a single patient with TRAPS remains unclear.
Conclusions. Etanercept does not abolish inflammatory attacks but improves disease activity allowing corticosteroid reduction. Etanercept may be clinically useful in replacing or reducing steroid requirements in the treatment of TRAPS. A formal trial of etanercept to establish its role in clinical management is indicated.
KEY WORDS: Tumour necrosis factor associated periodic syndrome, Etanercept, p55TNFr-Ig.
Correspondence to: E. Drewe. E-mail: liz.drewe{at}nottingham.ac.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Farasat, I. Aksentijevich, and J. R. Toro Autoinflammatory Diseases: Clinical and Genetic Advances Arch Dermatol, March 1, 2008; 144(3): 392 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Drewe, R.J. Powell, and E.M. McDermott Comment on: Failure of anti-TNF therapy in TNF Receptor 1-Associated Periodic Syndrome (TRAPS) Rheumatology, December 1, 2007; 46(12): 1865 - 1866. [Full Text] [PDF]
|
|
|
|
|
|
S. Jacobelli, M. Andre, J.-F. Alexandra, C. Dode, and T. Papo Failure of anti-TNF therapy in TNF Receptor 1-Associated Periodic Syndrome (TRAPS) Rheumatology, July 1, 2007; 46(7): 1211 - 1212. [Full Text] [PDF]
|
|
|
|
 |
|
 L Federici, C Rittore-Domingo, I Kone-Paut, C Jorgensen, M Rodiere, A Le Quellec, and I Touitou A decision tree for genetic diagnosis of hereditary periodic fever in unselected patients Ann Rheum Dis, November 1, 2006; 65(11): 1427 - 1432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ida, T. Aramaki, K. Arima, T. Origuchi, A. Kawakami, and K. Eguchi Successful treatment using tacrolimus (FK506) in a patient with TNF receptor-associated periodic syndrome (TRAPS) complicated by monocytic fasciitis Rheumatology, September 1, 2006; 45(9): 1171 - 1173. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Rudofsky Jr, F. Hoffmann, K. Muller, M. Filser, P. Lohse, J. Beimler, and V. Schwenger A nephrotic patient with tumour necrosis factor receptor-associated periodic syndrome, IgA nephropathy and CNS involvement Nephrol. Dial. Transplant., April 1, 2006; 21(4): 1109 - 1112. [Full Text] [PDF]
|
|
|
|
|
|
A. Simon, J. W. M. van der Meer, R. Vesely, U. Myrdal, K. Yoshimura, P. Duys, J. P. H. Drenth, and Contributing members of the International HIDS Stu Approach to genetic analysis in the diagnosis of hereditary autoinflammatory syndromes Rheumatology, March 1, 2006; 45(3): 269 - 273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Nowlan, E. Drewe, H. Bulsara, N. Esposito, R. A. Robins, P. J. Tighe, R. J. Powell, and I. Todd Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A Rheumatology, January 1, 2006; 45(1): 31 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Drewe, M. L. Huggins, A. G. Morgan, M. J. D. Cassidy, and R. J. Powell Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome Rheumatology, November 1, 2004; 43(11): 1405 - 1408. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Grateau Clinical and genetic aspects of the hereditary periodic fever syndromes Rheumatology, April 1, 2004; 43(4): 410 - 415. [Abstract] [Full Text] [PDF]
|
|